David Smadja/Wikipedia
Jun 7, 2025, 08:46
David Smadja: A Major Step Forward in The Fight Against Cancer-Related Thrombosis
David Smadja, Team Director “Endotheliopathy and hemostasis disorders” at INSERM The Paris Cardiovascular Research Center, shared a post on LinkedIn:
“A major step forward in the fight against cancer-related thrombosis!
In the journal VAINCRE LE CANCER – NRB, we take a look back at the API-CAT study, led by Prof. Isabelle Mahé (Louis Mourier Hospital AP-HP) and our team at PARCC – Inserm Endotheliopathy & Hemostasis Disorders.
Result? A reduced dose of apixaban is sufficient to prevent thromboembolic recurrence with less bleeding.
This is further proof that academic research is changing clinical practices. Proud to contribute to this breakthrough in the service of cancer patients.”
You can read a wide variety of new scientific posts in Hemostasis Today.
-
Oct 9, 2026, 13:48Maxime Dely: Raising Awareness for Blood Donation
-
Oct 9, 2026, 13:48Vera Ghali: Anemia in Myelofibrosis and Its Impact on Treatment Outcomes and Overall Survival
-
Oct 9, 2026, 13:32W David Freeman։ The Mechanical Penumbra in Intracerebral Hemorrhage and Its Potential for Tissue Recovery
-
Oct 9, 2026, 13:11Ayshathul Noora։ Carbetocin vs Oxytocin in Preventing Postpartum Hemorrhage
-
Oct 9, 2026, 13:07The Rebalanced Patient: New Therapies and New Thrombotic Risks in Hemophilia
-
Oct 9, 2026, 12:48Santiago Cepeda Chafla: CereBleed Simplifies Brain Hemorrhage Assessment
-
Oct 9, 2026, 12:34Abdul Muqtadir Abbasi: Pancytopenia Is a Finding, Not a Diagnosis
-
Oct 9, 2026, 12:24Mercy Lung’aho: When Diet Quality and Nutritional Biomarkers Tell Different Stories
-
Oct 9, 2026, 12:22Eugene Fan: Bridging Therapeutic Breakthroughs and Equitable Thalassaemia Care